ClinicalTrials.gg
CompletedNCT07262606Updated Oct 8, 2026

Salivary Mitofusin-1 Levels in Periodontitis: Associations With Disease Severity, Smoking, and Treatment Response

An interventional study of Non-surgical Periodontal Therapy (Scaling and Root Planing) and Saliva Collection in Periodontal Disease and Chronic Periodontitis (Disorder), sponsored by Ömer Faruk Okumuş. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.

Primary conditionChronic PeriodontitisRegistry: Periodontal DiseasesReclassifiedWhy we changed it
Registry
Periodontal Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Chronic Periodontitis
Why
  1. The study's listed conditions name Chronic Periodontitis, a narrower term within Periodontal Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Ömer Faruk Okumuş · Not applicable, Interventional, and Basic science

How we know

Updated Oct 8, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Chronic Periodontitis with a site in Turkey — 1 open to participants now, 1 under way, none of them phase 3. Chronic Periodontitis · Turkey.

Enrollment
3rd of 15
104 · median 30
Started
2025
the only one that year
No phase
12 of 26
1 open now
Registered
24th of 26
by date

Among the 26 studies in Chronic Periodontitis with a site in Turkey, this one is the 3rd largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2025, is one of 12 with no phase, and was the 24th registered.

Chronic Periodontitis

378 studies on the registry are indexed under Chronic Periodontitis; 21 are open to participants now.

Browse Chronic Periodontitis studies →

Open to participants now

1 of the 26 studies in Chronic Periodontitis with a site in Turkey is open now. Recruiting first, the newest first:

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 13 Chronic Periodontitis studies recruiting now, 7 (54%) set no upper age limit and 5 (38%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Chronic Periodontitis with a site in Turkey, or all of them as a file.
02

Study summary

Periodontitis (gum inflammation) is a common disease worldwide. This study aims to investigate a novel biomarker, a protein called Mitofusin-1 (Mfn1), in saliva that may be associated with the severity of periodontitis and response to treatment. The study will include periodontally healthy individuals, individuals with mild to severe periodontitis, and smokers with severe periodontitis. Participants will receive saliva samples and undergo clinical periodontal examinations. Individuals with periodontitis will receive standard periodontal treatment, and changes in Mfn1 levels will be assessed 3 months after treatment. The study is expected to shed light on the potential utility of Mfn1 as a marker in the diagnosis and follow-up of periodontitis.

03

Conditions studied

  • Periodontal Disease
  • Chronic Periodontitis (Disorder)

Browse trials for

Keywords

  • Mitofusin-1
  • Saliva
  • Biomarker
  • Periodontal Treatment
  • Smoking
04

In context

Chronic Periodontitis Reclassified

378 studies on the registry are indexed under Chronic Periodontitis; 21 are open to participants now.

This study's enrollment of 104 is above the median of 46 across 308 interventional studies indexed under Chronic Periodontitis.

Browse Chronic Periodontitis studies →

Lead sponsor

Ömer Faruk Okumuş is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Compared within Chronic Periodontitis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Periodontal Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide written .
  • Systemically healthy (no history of diabetes mellitus, immunodeficiency, , or other systemic conditions that could affect periodontal status).
  • Have a minimum of 20 natural teeth (excluding third molars).
  • No antibiotic therapy or periodontal treatment in the last 6 months.

For Healthy Control Group:

No clinical attachment loss. Probing depth ≤ 3 mm. No radiographic evidence of bone loss. Low gingival and plaque index scores.

For Mild Periodontitis Group:

Diagnosed with Stage I or II periodontitis according to the 2018 AAP/EFP classification.

Clinical attachment loss of 1-4 mm. Radiographic bone loss of ≤15-33%. Non-smoker.

For Severe Periodontitis Group:

Diagnosed with Stage III or IV periodontitis according to the 2018 AAP/EFP classification.

Clinical attachment loss ≥ 5 mm. Radiographic bone loss to the mid-advanced level of the root. Non-smoker.

For Severe Periodontitis with Smoking Group:

Meets all criteria for the Severe Periodontitis Group. Regular smoker (at least 10 cigarettes per day for a minimum of 5 years).

Exclusion criteria

Exclusion Criteria:

  • Fewer than 20 natural teeth (excluding third molars).
  • Presence of any systemic disease (e.g., diabetes mellitus, immunological disorders, cancer).
  • Use of antibiotics or receiving periodontal treatment in the last 6 months.
  • Pregnancy or lactation.
  • For non-periodontitis groups (Healthy Control): Any signs of periodontitis.
  • For periodontitis groups (all): History of smoking cessation for at least 5 years (must be either a current regular smoker or a never-smoker, depending on the group definition).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
104 participants (actual)

Study arms

  • Sham comparator
    Healthy Control Group

    Periodontally healthy individuals with no clinical attachment loss, probing depth ≤3 mm, no radiographic bone loss, and low gingival and plaque index scores.

    Other: Saliva Collection

  • Experimental
    Mild Periodontitis Group

    Non-smoking individuals diagnosed with Stage I-II periodontitis according to the AAP/EFP 2018 classification, with clinical attachment loss of 1-4 mm and ≤15-33% radiographic bone loss.

    Procedure: Non-surgical Periodontal Therapy (Scaling and Root Planing) · Other: Saliva Collection

  • Experimental
    Severe Periodontitis Group

    Non-smoking individuals diagnosed with Stage III-IV periodontitis according to the AAP/EFP 2018 classification, with clinical attachment loss ≥5 mm and radiographic bone loss to the mid-advanced level of the root.

    Procedure: Non-surgical Periodontal Therapy (Scaling and Root Planing) · Other: Saliva Collection

  • Experimental
    Severe Periodontitis with Smoking Group

    Individuals who meet the criteria for the Severe Periodontitis Group and are also regular smokers (at least 10 cigarettes per day for a minimum of 5 years).

    Procedure: Non-surgical Periodontal Therapy (Scaling and Root Planing) · Other: Saliva Collection

Interventions

  • ProcedureNon-surgical Periodontal Therapy (Scaling and Root Planing)

    A standard periodontal treatment procedure that involves the removal of dental plaque and calculus (tartar) from the tooth surfaces and root pockets. This is followed by root planing to smooth the root surfaces, allowing the gingiva to heal and reattach to the tooth.

  • OtherSaliva Collection

    Collection of unstimulated whole saliva. Participants will be asked to allow saliva to pool in the floor of the mouth and then passively drool into a sterile collection tube. A total of 1.5 ml of saliva will be collected from each participant.

07

What researchers measure

Primary outcomes

  1. Salivary Mitofusin-1 (Mfn1) Concentration at Baseline

    Mfn1 protein concentration in saliva measured using ELISA (ng/mL) at baseline in each study group.

    Time frame: Baseline

Secondary outcomes

  1. Change in Salivary Mfn1 Concentration After Periodontal Therapy

    Difference in salivary Mfn1 concentration (ng/mL) measured using ELISA at baseline and 3 months after non-surgical periodontal therapy in the periodontitis groups.

    Time frame: Baseline and 3 months

  2. Salivary Glutathione Peroxidase (GPx) Concentration

    GPx enzyme activity measured in saliva by spectrophotometric colorimetric assay (U/L).

    Time frame: Baseline

  3. Salivary 8-Hydroxy-2'-Deoxyguanosine (8-OHdG) Concentration

    8-OHdG concentration measured in saliva using ELISA (ng/mL).

    Time frame: Baseline

  4. Correlation Between Salivary Mfn1 Concentration and Probing Depth (PD)

    Correlation coefficient (r) between salivary Mitofusin-1 (Mfn1) concentration measured by ELISA (ng/mL) and probing depth measured with a manual periodontal probe (mm).

    Time frame: Baseline

  5. Correlation Between Salivary Mfn1 Concentration and Clinical Attachment Level (CAL)

    Correlation coefficient (r) between salivary Mitofusin-1 (Mfn1) concentration measured by ELISA (ng/mL) and clinical attachment level measured with a manual periodontal probe (mm).

    Time frame: Baseline

  6. Correlation Between Salivary Mfn1 Concentration and Plaque Index (PI)

    Correlation coefficient (r) between salivary Mitofusin-1 (Mfn1) concentration measured by ELISA (ng/mL) and plaque index assessed using the Silness-Löe Plaque Index (%).

    Time frame: Baseline

  7. Correlation Between Salivary Mfn1 Concentration and Gingival Index (GI)

    Correlation coefficient (r) between salivary Mitofusin-1 (Mfn1) concentration measured by ELISA (ng/mL) and gingival index assessed using the Löe-Silness Gingival Index (score).

    Time frame: Baseline

08

Study locations

1 site
  • Erzincan Binali Yıldırım University Faculty of Dentistry
    Erzincan, Erzincan 24002, Turkey (Türkiye)
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Apr 2026, 5 months.

Of 89 non-industry interventional studies with no phase under Chronic Periodontitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 24. This study's 5 months is below that.

Counting every sponsor, half of 90 studies reached it within 15 months; a quarter within 10 and three quarters within 24.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Feb 2026 → Apr 2026 and completion Nov 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 3, 2025
StartActual
Nov 1, 2025
Primary completionActual
Apr 15, 2026was Feb 2026
CompletionActual
Jul 1, 2026was Nov 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 8, 2026
Primary completion
Feb 15, 2026→Apr 15, 2026 (actual)
Oct 8, 2026
Study completion
Nov 1, 2026→Jul 1, 2026 (actual)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Recruiting→Completed
    Primary completion Feb 15, 2026→Apr 15, 2026 (now actual)
    Study completion Nov 1, 2026→Jul 1, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07262606
Lead sponsor
Ömer Faruk Okumuş
Responsible party
Ömer Faruk Okumuş (assistant professor, Erzincan University) — Sponsor-investigator
First posted
Dec 3, 2025
Start date
Nov 1, 2025
Primary completion
Apr 15, 2026
Completion
Jul 1, 2026
Last update
Oct 8, 2026

Study contacts

Ömer F Okumuş, DDS,PhD
principal investigator · Erzincan Binali Yıldırım University, Faculty of Dentistry, Department of Periodontology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion